Safeguard Investment Advisory Group’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-70
Closed 803
2020
Q4
$0 Buy
+70
New +$149 ﹤0.01% 808

Other funds holding BMY.RT

Safeguard Investment Advisory Group's BMY.RT Position: Q1 2021 in Review

Safeguard Investment Advisory Group sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 70 shares.

Safeguard Investment Advisory Group first reported a position in BMY.RT in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Safeguard Investment Advisory Group reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Safeguard Investment Advisory Group sold 70 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • Safeguard Investment Advisory Group first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2020 and held it in 1 quarter.
  • Safeguard Investment Advisory Group's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $0 in Q4 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Safeguard Investment Advisory Group's 13F filing for Q1 2021, filed 10 May 2021.